Kalbe Farma Tbk PT
IDX:KLBF

Watchlist Manager
Kalbe Farma Tbk PT Logo
Kalbe Farma Tbk PT
IDX:KLBF
Watchlist
Price: 1 225 IDR 2.08%
Market Cap: 57.3T IDR

Operating Margin

12.6%
Current
Declining
by 0.2%
vs 3-y average of 12.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
12.6%
=
Operating Income
Rp4.3T
/
Revenue
Rp34.4T

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
12.6%
=
Operating Income
Rp4.3T
/
Revenue
Rp34.4T

Peer Comparison

Country Company Market Cap Operating
Margin
ID
Kalbe Farma Tbk PT
IDX:KLBF
55.5T IDR
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
528.3B USD
Loading...
CH
Roche Holding AG
SIX:ROG
275.5B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
210.3B GBP
Loading...
CH
Novartis AG
SIX:NOVN
220.8B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.4B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.1B USD
Loading...

Market Distribution

In line with most companies in Indonesia
Percentile
69th
Based on 1 283 companies
69th percentile
12.6%
Low
-111 644.7% — 0%
Typical Range
0% — 12.9%
High
12.9% — 524 864.9%
Distribution Statistics
Indonesia
Min -111 644.7%
30th Percentile 0%
Median 6.1%
70th Percentile 12.9%
Max 524 864.9%

Kalbe Farma Tbk PT
Glance View

Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.

KLBF Intrinsic Value
HIDDEN
Show
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
12.6%
=
Operating Income
Rp4.3T
/
Revenue
Rp34.4T
What is Kalbe Farma Tbk PT's current Operating Margin?

The current Operating Margin for Kalbe Farma Tbk PT is 12.6%, which is below its 3-year median of 12.9%.

How has Operating Margin changed over time?

Over the last 3 years, Kalbe Farma Tbk PT’s Operating Margin has decreased from 15% to 12.6%. During this period, it reached a low of 11.9% on Dec 31, 2023 and a high of 15% on Sep 30, 2022.

Back to Top